Each common unit consists of one common share and one warrant. Each warrant will expire five years from date of issuance. ThinkEquity is the underwriter for this offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Therapeutics: Promising Phase 3 Trial Progress and Strategic Financial Management Justify Buy Rating
- BriaCell Advances Phase 3 Study in Metastatic Breast Cancer
- BriaCell announces ongoing Phase 3 study enrolled over 75 patients
- BriaCell’s Phase 2 Study Shows Promising Survival Data in Breast Cancer
- BriaCell announces survival data from its Phase 2 study of Bria-IMT